Table 3.

Proportion of patients reaching secondary or exploratory end points

	CBM n= 7	Placebo n= 9	Difference (%) (95% CI)
No delayed emesis	5 (71.4%)	2 (22.2%)	49.2 (1.0, 75.0)
No delayed nausea*	4 (57.1%)	2 (22.2%)	34.9 (−10.8, 66.3)
No significant delayed nausea†	5 (71.4%)	4 (44.4%)	27.0 (−18.0, 59.7)
Not valued	1‡ (14.3%)	–

^*Nausea VAS score of ≤10 mm.

^†Nausea VAS score of ≤25 mm.

^‡One patient in the CBM group discontinued treatment after the first three doses in the hospital and did not complete the assessment questionnaire.